Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Sodium metavanadate is a vanadium compound that has been investigated scientifically for its potential effects on metabolic syndrome, primarily in preclinical (animal and cell culture) studies. Metabolic syndrome is characterized by a cluster of conditions such as insulin resistance, hyperglycemia, dyslipidemia, and hypertension. Vanadium compounds, including sodium metavanadate, have demonstrated insulin-mimetic properties in vitro and in animal models, with some studies showing improved glucose tolerance, reduced blood glucose levels, and beneficial effects on lipid profiles. The proposed mechanisms involve modulation of insulin signaling pathways and enhancement of glucose uptake by cells. However, the evidence is limited to laboratory and animal studies; there have not been robust, large-scale clinical trials in humans to confirm safety or efficacy for metabolic syndrome.

Some small, early human studies with other vanadium salts (like vanadyl sulfate) suggested minor improvements in glycemic control in diabetic patients, but these findings have not led to regulatory approval or widespread clinical use due to concerns about toxicity and insufficient efficacy data. Sodium metavanadate itself has not been widely studied in humans for this indication. Thus, while there is scientific interest and preliminary evidence, the overall quality and quantity of evidence are limited, and the risk of toxicity restricts clinical application. The current scientific consensus does not support the routine use of sodium metavanadate for metabolic syndrome outside of research settings.

More about Sodium Metavanadate
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Sodium Metavanadate

Products containing Sodium Metavanadate